The Alzheimer myth and biomarker research in dementia

Journal of Alzheimer's Disease

Volumn 31, Issue SUPPL. 3, 2012, Pages

  Richard, Edo ^a   Schmand, Ben ^a   Eikelenboom, Piet ^a   Westendorp, Rudi G ^b   Van Gool, Willem A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; biomarkers; cerebrospinal fluid; magnetic resonance imaging; neuroimaging; old age dementia; prevention

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; DEMENTIA; DIABETES MELLITUS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HYPERTENSION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 84866872850     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112216     Document Type: Article

References (49)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117.
2. Schoenmaker N, Van Gool WA (2004) The age gap between patients in clinical studies and in the general population: A pitfall for dementia research. Lancet Neurol 3, 627-630.
3. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
4. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800.
5. Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, Libow LS, Lesser GT, Maroukian M, Grossman HT (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65, 1211-1217.
6. Middleton LE, Grinberg LT, Miller B, Kawas C, Yaffe K (2011) Neuropathologic features associated with Alzheimer disease diagnosis: Age matters. Neurology 77, 1737-1744.
7. Jagust WJ,Mormino EC (2011) Lifespan brain activity, betaamyloid, and Alzheimer's disease. Trends Cogn Sci 15, 520- 526.
8. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357, 169-175.
9. BennettDA, Schneider JA, Arvanitakis Z,Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two communitybased studies. Neurology 66, 1837-1844.
10. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197- 2204.
11. Esiri MM, Nagy Z, Smith MZ, Barnetson L, SmithAD(1999) Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354, 919-920.
12. Gold G, Giannakopoulos P, Herrmann FR, Bouras C,Kovari E (2007) Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 130, 2830-2836.
13. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817.
14. Castellani RJ, Lee HG, Zhu X, Perry G, Smith MA (2008) Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 67, 523-531.
15. Eikelenboom P, Veerhuis R, van EE, Hoozemans JJ, Rozemuller AJ, Van Gool WA (2011) The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: Neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8, 142-150.
16. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J,Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van BC, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N,Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
17. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, FievetN, Barberger-Gateau P, Engelborghs S, De DP, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van BC, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
18. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, LongstrethWTJr, JanssensAC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832-1840.
19. DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 99, 10843-10848.
20. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA (2008) Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28, 6333-6341.
21. Van Gool WA, Eikelenboom P (2000) The two faces of Alzheimer's disease. J Neurol 247, 500-505.
22. Rebeck GW, Perls TT,West HL, Sodhi P, Lipsitz LA, Hyman BT (1994) Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology 44, 1513-1516.
23. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de LM, Hampel H, Scheltens P, Pirttila T,Wallin A, Jonhagen ME, Minthon L,Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
24. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR (2006) Age and apolipoprotein E.*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63, 936-939.
25. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
26. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM (2009) CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30, 1895-1901.
27. Schmand B, Eikelenboom P, Van Gool WA (2011) Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts. J Am Geriatr Soc 59, 1705-1710.
28. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de LM, Hampel H, Scheltens P, Pirttila T,Wallin A, Jonhagen ME, Minthon L,Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
29. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger- Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
30. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE (2011) Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 68, 961-969.
31. Schmand B, Huizenga HM, Van Gool WA (2010) Metaanalysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 40, 135-145.
32. Schmand B, Eikelenboom P, Van Gool WA (2012) Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis 29, 641-648.
33. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst, RevCD005593
34. Birks J, Grimley EJ, Iakovidou V, Tsolaki M, Holt FE (2009) Rivastigmine for Alzheimer's disease Cochrane Database Syst Rev, CD001191.
35. Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, Perry R, O'brien J (1999) White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 67, 66-72.
36. Langa KM, Foster NL, Larson EB (2004) Mixed dementia: Emerging concepts and therapeutic implications. JAMA 292, 2901-2908.
37. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA (2009) Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc 57, 797-805.
38. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C (2008) Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol 7, 683-689.
39. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E (2010) Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review. Vasc Health Risk Manag 6, 775-785.
40. Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, Gold G, Gomez F, Guimaraes R, Gustafson D, Khachaturian A, Luchsinger J, Mangialasche F, Mathiex-Fortunet H, Michel JP, Richard E, Schneider LS, Solomon A, Vellas B (2011) IAGG workshop: Health promotion program on prevention of late onset dementia. J Nutr Health Aging 15, 562-575.
41. Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B (2009) Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008". The Multidomain Alzheimer PreventiveTrial (MAPT):Anew approach to the prevention of Alzheimer's disease. Alzheimers Dement 5, 114-121.
42. Richard E, Van den Heuvel E, Moll van Charante EP, Achthoven L,Vermeulen M, Bindels PJ,Van GoolWA(2009) Prevention of dementia by intensive vascular care (PreDIVA): A cluster-randomized trial in progress. Alzheimer Dis Assoc Disord 23, 198-204.
43. Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, Gold G, Gomez F, Guimaraes R, Gustafson D, Khachaturian A, Luchsinger J, Mangialasche F, Mathiex-Fortunet H, Michel JP, Richard E, Schneider LS, Solomon A, Vellas B (2010) Health promotion program on prevention of late onset dementia. J Nutr Health Aging 15, 562-575.
44. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT Jr, Luchsinger JA (2009) Midlife and late-life obesity and the risk of dementia: Cardiovascular health study. Arch Neurol 66, 336-342.
45. Mielke MM, Zandi PP, Shao H, Waern M, Ostling S, Guo X, Bjorkelund C, Lissner L, Skoog I, Gustafson DR (2010) The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 75, 1888-1895.
46. Qiu C, Winblad B, Fratiglioni L (2005) The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4, 487-499.
47. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5, 64-74.
48. Richards M, Brayne C (2010) What do we mean by Alzheimer's disease? BMJ 341, c4670.
49. Richard E, Van Gool WA (2010) Alzheimer's disease/syndrome? There are two types of disease. BMJ 341, c6327.